1997
DOI: 10.1590/s0036-46651997000200002
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: In the search for Leishmania recombinant antigens that can be used as a vaccine against American Cutaneous Leishmaniasis, we identified a Leishmania (Leishmania) amazonensis recombinant protein of 33 kD (Larp33) which is recognized by antibodies and peripheral blood leukocytes (PBL) from subjects vaccinated with Leishvacin, Larp33 was expressed in Escherichia coli after cloning of a 2.2 kb Sau3 digested genomic fragment of L. (L.) amazonensis into the pDS56-6 His vector. Immunoblotting analysis indicated that … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
4
0
1

Year Published

1999
1999
2014
2014

Publication Types

Select...
6
1

Relationship

3
4

Authors

Journals

citations
Cited by 7 publications
(5 citation statements)
references
References 44 publications
0
4
0
1
Order By: Relevance
“…This method has used soluble extracts, 15,18,20,21,44 purified membrane proteins, 45 or recombinant proteins as antigens. [46][47][48] The immunoblot results obtained with soluble protein extracts of Leishmania species and strain 268T showed a complex reactivity pattern (Figures 1-4), in which most (93%) of the polypeptide fractions of parasites were recognized by at least one serum sample from the individuals tests. Similarly complex profiles were found 15,49 when the human antibody specificity to antigens of L. (V.) braziliensis and L. infantum was analyzed by Western blotting.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…This method has used soluble extracts, 15,18,20,21,44 purified membrane proteins, 45 or recombinant proteins as antigens. [46][47][48] The immunoblot results obtained with soluble protein extracts of Leishmania species and strain 268T showed a complex reactivity pattern (Figures 1-4), in which most (93%) of the polypeptide fractions of parasites were recognized by at least one serum sample from the individuals tests. Similarly complex profiles were found 15,49 when the human antibody specificity to antigens of L. (V.) braziliensis and L. infantum was analyzed by Western blotting.…”
Section: Discussionmentioning
confidence: 99%
“…Western blotting showed that Larp33 was a 40-kD protein expressed in L. (L.) amazonensis and L. (V.) brazilliensis. 47 A protein with an MW r of 50 kD, which was recognized by more than 50.00% of the ATL-positive sera, was detected in extracts from L. (L.) amazonensis, L. tropica, and strain 268T (Table 4). However, only 23.00% of the ATL-positive sera recognized the 50-kD fraction in the L. (V.) braziliensis extract.…”
Section: Discussionmentioning
confidence: 99%
“…Reports from different laboratories have shown that purified protein and recombinant Leishmania antigens, such as the gp46, gp63 and 33kDa, can induce partial protection against Leishmania infection in animal models (CHAMPSI & McMAHON-PRATT, 1988;RUSSELL & ALEXANDER, 1988;BUTTON & McMASTER, 1988;FERNANDES et al, 1997).…”
Section: Discussionmentioning
confidence: 99%
“…Apesar do número extremamente elevado de estudos com vacinas de primeira geração, não só nas Américas, como no Velho Mundo, com muitos resultados positivos, tais preparações estão muito longe de serem liberadas para produção e utilização em larga escala, principalmente em virtude de problemas relacionados a sua padronização e estabilidade. Por esse motivo, alguns grupos de pesquisa brasileiros estudam a possibilidade de seleção de frações antigênicas ou mesmo de antígenos definidos, presentes na Leishvacin®, que possam ser utilizados em uma futura vacina (profilática ou terapêutica) mais bem definida contra a leishmaniose tegumentar ou em um futuro teste diagnóstico (Fernandes et al, 1997;Cardoso et al, 2003;Telino et al, 2006).…”
Section: Vacinas De Primeira Geraçãounclassified